weight loss drug

2025.09.24

10:15

A-share weight loss drug concepts fluctuated higher, with Xinlitai rising more than 8%. Ganli Pharmaceutical had previously hit the daily limit, and Lanxiao Technology, Sinopharm, Tonghua Dongbao, and Huadong Medicine were among the top gainers.

2025.09.22

13:39

In the afternoon, weight loss drug concepts plunged and fell, with Borrui Pharmaceutical falling more than 10%.

In the afternoon, the concept of weight loss drugs plunged and fell. Borrui Pharmaceutical fell more than 10%, after rising more than 9% before. Zhongsheng Pharmaceutical fell more than 7%, followed by Tainkang, Sinovac Biotech, Baihua Pharmaceutical, and Jinkai BioScience.

13:37

Many A-share weight loss drug concept stocks fell in the afternoon, with Borrui Pharmaceutical plunging more than 12%, having risen nearly 10% in the morning; Zhongsheng Pharmaceutical fell more than 8%.

11:52

According to the Financial Times: Pfizer is close to acquiring the weight loss drug company Metsera for $7.3 billion.

2025.09.18

14:58

Morgan Stanley: Eli Lilly's oral weight loss drug clinical trial data is impressive, maintaining target price at $1,028

Morgan Stanley's research report stated that Eli Lilly's oral GLP-1 receptor agonist Orfor has performed well in weight loss, improvement of cardiovascular metabolic indicators and safety. The newly released data has not changed its positive view on Orfor's prospects. It maintains an "overweight" rating and a target price of US$1,028 in the next 12 months.

2025.09.11

10:30

Innovative drug stocks plummeted as reports emerged that the Trump administration was preparing an executive order targeting Chinese pharmaceuticals.

Innovative drug stocks plummeted in early trading today (September 11th), with CXO-related, weight loss, and innovative drug concepts all falling by over 1%. Even leading innovative drug companies with a market value exceeding 100 billion yuan were not immune to the correction, with BeiGene-U and Hengrui Medicine both falling by over 5%. On the news front, it was reported that the Trump administration is considering an executive order targeting Chinese pharmaceuticals.

2025.09.03

09:44

The ChiNext Index rose over 1%, the Shenzhen Component Index rose over 0.5%, and the Shanghai Composite Index rose 0.05%. Precious metals, gaming, and diet pills led the gains.

2025.08.26

21:36

Eli Lilly (LLY.N) rose 4% as the company plans to apply for approval of a weight loss drug in 2025.

18:54

Eli Lilly (LLY.N) announced results from a second obesity trial of orforglipron, showing the drug reduced weight by 9.6% in patients with obesity and diabetes. The company plans to apply for approval of the weight loss drug in 2025.

2025.08.21

10:41

The ChiNext Index turned positive again, biopharmaceutical concepts rebounded, and concepts such as CRO, weight loss drugs, innovative drugs, and AI pharmaceuticals strengthened.

2025.08.07

22:00

Eli Lilly (LLY.N) fell nearly 14 percent, its biggest one-day drop since August 2000. The company's oral weight-loss drug failed to perform as expected.

21:30

At the US stock market opening, the Dow Jones Industrial Average rose 0.54%, the S&P 500 rose 0.55%, and the Nasdaq Composite rose 0.73%. Intel (INTC.O) fell over 2% after Trump urged the company's CEO to resign immediately. Eli Lilly (LLY.N) fell nearly 10% after the company's oral weight loss drug failed to perform as expected. Apple (AAPL.O) continued its gains from the previous day, opening up 2.3%.

2025.08.06

14:46

Novo Nordisk (NVO.N) CEO: The global branded weight loss drug market has doubled since last year.

2025.08.05

09:46

A-share weight loss drug concept stocks rebounded, with Minopharm hitting the daily limit, followed by Hanyu Pharmaceutical, Jinkai Biosciences, Ganli Pharmaceutical, Sichuan Shuangma, Fengyuan Pharmaceutical, and Changshan Pharmaceutical.

2025.08.01

19:45

Novo Nordisk and Eli Lilly rose in pre-market trading as the US may consider insurance coverage for weight loss drugs.

Novo Nordisk shares rose 1.9% in pre-market trading, while Eli Lilly and Company rose 1.5% following reports that the United States will consider insurance coverage for weight loss drugs.

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Musk: XAI will certainly raise funds in the next few months, but not now
                            2025-09-20

                                    Nvidia (NVDA.O) fell further, dropping nearly 3%.
                            2025-09-17

                                    SoftBank and OpenAI's AI joint venture in Japan is severely delayed, with an update now expected in November.
                            2025-09-18

                                    HGTECH's 3.2T NPO products are used by leading industry customers
                            2025-09-24

                                    Alipay's two operating entities have completed the name change
                            2025-09-19